menu toggle

Global consulting and market access

Transforming evidence and market intelligence into effective global market access strategies and solutions. 
global market access international consulting amerisourcebergen pharmalex

Delivering patients healthier futures wherever they are in the world

Our goal is to help you speed time to market and maximize your product’s success

  • Engage - early with stakeholders
  • Monitor - global and local Health Technology (HTA) landscape
  • Design - strong evidence and submission packages
  • Leverage - opportunities for HTA interactions & generate real-world evidence
  • Communicate - your product's value
  • Apply - critical health economics and outcomes research information

100+

countries

1,300+

global locations

50+%

projects are global

Our global biopharma consulting capabilities

When launching products in Europe and HTA countries, we provide deep understanding of the environment, competition, and considerations for market access. We evaluate how your product many be viewed by payers and assess what may be needed beyond your clinical trials. We can help you engage early with key decision-makers and provide timely advice on strategy and execution.

Health economics & outcomes research

Work with industry-recognized experts who apply scientific methodologies to conduct the full scope of health economics and outcomes research for effective strategic planning. We combine rigorous, technical expertise with an understanding of local markets and multiple disease states to deliver relevant, transparent, and credible results to help inform practical strategies and tactics that communicate a robust portfolio of value-based evidence.

Market access consulting

When launching products outside the U.S., we provide deep understanding of the environment, competition, and considerations for market access across Europe and HTA countries. We evaluate how your product many be viewed by payers and assess what may be needed beyond your clinical trials. 

Real-world evidence

With strategic global data partnerships in the US, Germany, the UK, the Netherlands, France, Sweden, Canada, Japan, and China, we support our clients' global strategies along the entire product lifecycle.

Our databases are sourced from administrative claims, electronic medical records, or disease registries, and capture patient-level health information and outcomes for healthcare services performed in various care settings.

Regulatory affairs

Our global team offers the full range of regulatory services needed to enter and operate in international markets. Our strong foundation of technical, regulatory, and scientific expertise, makes us uniquely positioned to support pharmaceutical operations worldwide.

Patient Safety (Pharmacovigilance)

Along the whole product lifecycle from discovery through launch, our international team provides true end-to-end solutions for pharmacovigilance system & operation as well as benefit-risk-management services. Our global footprint enables us to cover all needs worldwide, on local affiliate level as well as for the global & headquarter functions.

Quality management and compliance

From innovation to commercialization, our global teams provide strategy consultancy on all things that impact the quality and compliance of the final product.

Unlock the future of healthcare 

Visit our resource center to find out more about the EU Joint Clinical Assessment (JCA) journey.
PharmaLex Acquisition

In the News

Cencora (formerly AmerisourceBergen) completes acquisition of PharmaLex in January 2023

The acquisition of PharmaLex enhances Cencora’s growth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services capabilities. PharmaLex’s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance services expand AmerisourceBergen’s role as partner of choice for biopharmaceutical partners across the pharmaceutical development and commercialization journey. 

Biopharma companies looking to launch products in Europe need to understand – and plan for – the factors that influence the approval and decision-making processes related to reimbursement, coverage and pricing, such as the transition to European Union (EU) joint clinical assessments, which will start for oncology and advanced therapies in 2025 as part of new health technology assessment (HTA) processes. Cencora consultants have the expertise and experience required to help you navigate your next global launch against rapidly evolving markets."

Tommy Bramley, PhD
Senior Vice President, Global Consulting
Cencora

Map of Europe

Ask local experts from markets worldwide

Global market access network

Understand the nuances of key international markets through our Global Market Access Network. This proprietary panel of advisors is composed of healthcare and payer experts who have the experience, insight, and relationships to help with formal documentation, evidentiary demands, and all aspects of the complex submission processes in more than 22 countries around the world.

Global market access and consulting insights

New pan-EU HTA: How can biopharma navigate the joint clinical assessment?

The new European Union (EU) Health Technology Assessment (HTA) regulation was enacted in January 2022 with the primary objective of streamlining the clinical assessment process for EU member states' HTA bodies. Biopharma companies need to be aware of the clinical development and market access processes in this uncharted environment. Enter your information below to read about how biopharma can approach their planning more successfully.

Three questions to ask about your market access partner

The new 2022 European Union (EU) health technology assessment (HTA) regulation is intended to streamline assessment of clinical data across the EU and minimize duplication of effort, for both health technology developers and HTA bodies. We consider what the new regulation means for health technology developers, particularly in terms of evidence submission requirements and what can be done to influence the implementation of the new regulation.

The new EU regulation on health technology assessment: Major change or minor adjustment?

Taking into account different comparator products, HTA methodologies and policy questions in individual member states and the need for submission of country-specific economic evidence, we consider what the new 2022 European Union (EU) health technology assessment (HTA) regulation means for health technology developers, particularly in terms of evidence submission requirements and what can be done to influence the implementation of the new regulation.

subscribe to HTA quarterly

HTA Quarterly

Each edition of HTA Quarterly provides insights and analysis from global experts with local market expertise on key priorities and perspectives affecting HTA. From therapeutic area spotlights to geographic reviews to critical industry topics, keep current on HTA activity around the globe with HTA Quarterly. Browse the archive and subscribe to the quarterly newsletter today. 
biopharma commercialization

Biopharma Services

Each investment we make is focused on connecting healthcare stakeholders to accelerate healthier futures. Our unrivaled expertise powers us in our vision to help you fully realize your product’s power—through the patients it reaches and the strategic outcomes it delivers. Learn more about our end to end suite of commercialization solutions for biopharma companies.

Let's work together to envision new paths to healthier futures around the world.

Start a conversation

Our global market access consulting team oversees strategy and tactics to ensure alignment with local requirements. Contact us today and our team of international consultants can help you work through your next launch, wherever that may be.